ArticleCurrent oncology (Toronto, Ont.)2015
Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations.
Article in Current oncology (Toronto, Ont.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.Current oncology (Toronto, Ont.) · 2018Pooled it
- Pooled it
- Efficacy and safety of rivaroxaban for the treatment of PICC-related upper extremity deep vein thrombosis in cancer patients: a retrospective study.Thrombosis journal · 2023Article
- Challenging clinical scenarios for therapeutic anticoagulation: A practical approach.Thrombosis research · 2022Review
- Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.Vascular medicine (London, England) · 2020Article
- Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism.EJHaem · 2020Article
- Cancer-associated thromboembolism: antithrombotic management of hospitalized patients.Journal of thrombosis and thrombolysis · 2020Observational
- [Modern treatment of deep vein thrombosis and pulmonary embolism].Der Internist · 2019Review
- Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill.Thrombosis journal · 2019Review
- Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.Journal of thrombosis and haemostasis : JTH · 2018Article
- Managing thrombosis in cancer patients.Research and practice in thrombosis and haemostasis · 2018Review
- Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson Practice.Frontiers in cardiovascular medicine · 2018Article
- Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins.Frontiers in medicine · 2017Review
- Venous thrombosis and cancer: from mouse models to clinical trials.Journal of thrombosis and haemostasis : JTH · 2015Review
- Clinical analysis of tumor and non-tumor patients complicated with pulmonary embolism.International journal of clinical and experimental medicine · 2015Article
- Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism is a common complication in cancer patients, and thromboembolism is the second most common cause of death after cancer progression. A number of clinical practice guidelines provide recommendations for the management of cancer-associated thrombosis. However, the guidelines lack recommendations covering commonly encountered clinical challenges (for example, thrombocytopenia, recurrent venous thromboembolism, etc.) for which little or no evidence exists. Accordingly, recommendations were developed to provide expert guidance to medical oncologists and other health care professionals caring for patients with cancer-associated thrombosis. The current expert consensus was developed by a team of 21 clinical experts. For each identified clinical challenge, the literature in medline, embase, and Evidence Based Medicine Reviews was systematically reviewed. The quality of the evidence was assessed, summarized, and graded. Consensus statements were generated, and the experts voted anonymously using a modified Delphi process on their level of agreement with the various statements. Statements were progressively revised through separate voting iterations and were then finalized. Clinicians using these recommendations and suggestions should tailor patient management according to the risks and benefits of the treatment options, patient values and preferences, and local cost and resource allocations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.